PARPi: Precision Medicine in Advanced Prostate Cancer (2023)

CME Available: https://auau.auanet.org/node/39597

At the conclusion of this activity, the learner will be able to:
1. Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class.
2. Describe the role of PARPi treatment alone and in combination with other cancer based therapies.
3. Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors.
4. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.

ACKNOWLEDGEMENT
This educational activity is supported by an independent educational grant from:
Pfizer, Inc.